^
Association details:
| Biomarker: | ATM mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Niraparib and irinotecan combination in ATM-mutated colorectal cancer
Published date:
09/14/2020
Excerpt:
Strong synergistic activity of low-dose combinations of SN38 and niraparib was found in cell lines carrying a pathogenic mutation in ATM....This work demonstrates that the subset of CRCs carrying heterozygous ATM mutations may benefit from a combination treatment with low doses of niraparib and irinotecan.
Secondary therapy:
irinotecan
